Cargando…

Human Induced Pluripotent Stem Cells as a Screening Platform for Drug-Induced Vascular Toxicity

Evaluation of potential vascular injury is an essential part of the safety study during pharmaceutical development. Vascular liability issues are important causes of drug termination during preclinical investigations. Currently, preclinical assessment of vascular toxicity primarily relies on the use...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tu, Chengyi, Cunningham, Nathan J., Zhang, Mao, Wu, Joseph C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8006367/ https://www.ncbi.nlm.nih.gov/pubmed/33790786 http://dx.doi.org/10.3389/fphar.2021.613837

Ejemplares similares

High-Throughput Drug Screening System Based on Human Induced Pluripotent Stem Cell-Derived Atrial Myocytes ∼ A Novel Platform to Detect Cardiac Toxicity for Atrial Arrhythmias
por: Honda, Yayoi, et al.
Publicado: (2021)

Human Pluripotent Stem Cells for Modeling of Anticancer Therapy-Induced Cardiotoxicity and Cardioprotective Drug Discovery
por: Keung, Wendy, et al.
Publicado: (2021)

Building Multi-Dimensional Induced Pluripotent Stem Cells-Based Model Platforms to Assess Cardiotoxicity in Cancer Therapies
por: Thomas, Dilip, et al.
Publicado: (2021)

Reproducibility of drug-induced effects on the contractility of an engineered heart tissue derived from human pluripotent stem cells
por: Arefin, Ayesha, et al.
Publicado: (2023)

Integrated Isogenic Human Induced Pluripotent Stem Cell–Based Liver and Heart Microphysiological Systems Predict Unsafe Drug–Drug Interaction
por: Lee-Montiel, Felipe T., et al.
Publicado: (2021)

Protocol to measure contraction, calcium, and action potential in human-induced pluripotent stem cell-derived cardiomyocytes
por: Zhang, Joe Z., et al.
Publicado: (2021)

Evaluation of chronic drug-induced electrophysiological and cytotoxic effects using human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs)
por: Altrocchi, C., et al.
Publicado: (2023)

A human pluripotent stem cell platform for assessing developmental neural toxicity screening
por: Hou, Zhonggang, et al.
Publicado: (2013)

Postponement of the opacification of lentoid bodies derived from human induced pluripotent stem cells after lanosterol treatment—the first use of the lens aging model in vitro in cataract drug screening
por: Zhang, Lifang, et al.
Publicado: (2022)

Drug screening platform using human induced pluripotent stem cell‐derived atrial cardiomyocytes and optical mapping
por: Gunawan, Marvin G., et al.
Publicado: (2020)

Human induced pluripotent stem cell–derived liver-on-a-chip for studying drug metabolism: the challenge of the cytochrome P450 family
por: Tamargo-Rubio, Isabel, et al.
Publicado: (2023)

Aminophylline Induces Two Types of Arrhythmic Events in Human Pluripotent Stem Cell–Derived Cardiomyocytes
por: Klimovic, Simon, et al.
Publicado: (2022)

Induced Pluripotent Stem Cells-Derived Mesenchymal Stem Cells Attenuate Cigarette Smoke-Induced Cardiac Remodeling and Dysfunction
por: Liang, Yingmin, et al.
Publicado: (2017)

New Modalities of 3D Pluripotent Stem Cell-Based Assays in Cardiovascular Toxicity
por: Orsolits, Barbara, et al.
Publicado: (2021)

Drug Development and the Use of Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Disease Modeling and Drug Toxicity Screening
por: Ovics, Paz, et al.
Publicado: (2020)

Ca(2+)-Currents in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes Effects of Two Different Culture Conditions
por: Uzun, Ahmet U., et al.
Publicado: (2016)

Effects of Antiarrhythmic Drugs on hERG Gating in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes From a Patient With Short QT Syndrome Type 1
por: Huang, Mengying, et al.
Publicado: (2021)

Motor neuron-derived induced pluripotent stem cells as a drug screening platform for amyotrophic lateral sclerosis
por: Amorós, Mariana A., et al.
Publicado: (2022)

Miniaturized droplet microarray platform enables maintenance of human induced pluripotent stem cell pluripotency
por: Liu, Yanxi, et al.
Publicado: (2021)

miR-199a Overexpression Enhances the Potency of Human Induced-Pluripotent Stem-Cell–Derived Cardiomyocytes for Myocardial Repair
por: Bian, Weihua, et al.
Publicado: (2021)

Stem cell‐derived extracellular vesicles reduce the expression of molecules involved in cardiac hypertrophy—In a model of human-induced pluripotent stem cell-derived cardiomyocytes
por: Constantin, Alina, et al.
Publicado: (2022)

Neglected, Drug-Induced Platinum Accumulation Causes Immune Toxicity
por: Zhang, Yuling, et al.
Publicado: (2020)

Disease-specific induced pluripotent stem cells: a platform for human disease modeling and drug discovery
por: Jang, Jiho, et al.
Publicado: (2012)

Induced pluripotent stem cell-derived cardiomyocytes for cardiovascular disease modeling and drug screening
por: Sharma, Arun, et al.
Publicado: (2013)

An Efficient Platform for Astrocyte Differentiation from Human Induced Pluripotent Stem Cells
por: TCW, Julia, et al.
Publicado: (2017)

Human induced pluripotent stem cell-based platform for modeling cardiac ischemia
por: Häkli, Martta, et al.
Publicado: (2021)

Human pluripotent stem cells on artificial microenvironments: a high content perspective
por: Viswanathan, Priyalakshmi, et al.
Publicado: (2014)

Human Induced Pluripotent Stem Cell as a Disease Modeling and Drug Development Platform—A Cardiac Perspective
por: Bekhite, Mohamed M., et al.
Publicado: (2021)

Screening of Novel Pharmacogenetic Candidates for Mercaptopurine-Induced Toxicity in Patients With Acute Lymphoblastic Leukemia
por: Cao, Minyuan, et al.
Publicado: (2020)

Disease modeling and drug screening for neurological diseases using human induced pluripotent stem cells
por: Xu, Xiao-hong, et al.
Publicado: (2013)

Human Pluripotent Stem Cell-Derived Neural Cells as a Relevant Platform for Drug Screening in Alzheimer’s Disease
por: Garcia-Leon, Juan Antonio, et al.
Publicado: (2020)

An Evaluation of Human Induced Pluripotent Stem Cells to Test for Cardiac Developmental Toxicity
por: Walker, Lauren Michelle, et al.
Publicado: (2021)

Metabolite signatures of doxorubicin induced toxicity in human induced pluripotent stem cell-derived cardiomyocytes
por: Chaudhari, Umesh, et al.
Publicado: (2017)

Induced Pluripotent Stem Cells Inhibit Bleomycin-Induced Pulmonary Fibrosis in Mice through Suppressing TGF-β1/Smad-Mediated Epithelial to Mesenchymal Transition
por: Zhou, Yan, et al.
Publicado: (2016)

Screening for Small Molecule Inhibitors of Statin-Induced APP C-terminal Toxic Fragment Production
por: Poksay, Karen S., et al.
Publicado: (2017)

Induced Pluripotent Stem Cell-Based Drug Screening by Use of Artificial Intelligence
por: Kusumoto, Dai, et al.
Publicado: (2022)

A high-content platform to characterise human induced pluripotent stem cell lines
por: Leha, Andreas, et al.
Publicado: (2016)

Astrocyte alterations in neurodegenerative pathologies and their modeling in human induced pluripotent stem cell platforms
por: Oksanen, Minna, et al.
Publicado: (2019)

Hydroxychloroquine-induced Retinal Toxicity
por: Yusuf, Imran H., et al.
Publicado: (2023)

Functional Vascular Endothelium Derived from Human Induced Pluripotent Stem Cells
por: Adams, William J., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_4ucfu3od7o9up52m5s48udgoe7